Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

IMPORTANCE:. Anaphylatoxin C5a, a proinflammatory complement split product, plays a central role in mediating organ dysfunction. OBJECTIVES:. This phase II clinical trial was conducted to study safety, tolerability, pharmacokinetics, and pharmacodynamics of vilobelimab, a recombinant monoclonal anti...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Bauer, MD, Andreas Weyland, MD, Gernot Marx, MD, Frank Bloos, MD, PhD, Stephan Weber, Dipl. Stat., Norbert Weiler, MD, Stefan Kluge, MD, Anja Diers, MD, Tim Philipp Simon, MD, Ingmar Lautenschläger, MD, Matthias Gründling, MD, Ulrich Jaschinski, MD, Philipp Simon, MD, Axel Nierhaus, MD, Onnen Moerer, MD, Lorenz Reill, MD, Achim Jörres, MD, Renfeng Guo, MD, Markus Loeffler, MD, Konrad Reinhart, MD, Niels Riedemann, MD, for the SepNet-Study Group
Format: article
Language:EN
Published: Wolters Kluwer 2021
Subjects:
Medical emergencies. Critical care. Intensive care. First aid
RC86-88.9
Online Access:https://doaj.org/article/425409c1c667424ab3c5530f15b92a63
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items